| Analysis of the human endogenous coregulator complexome A Malovannaya, RB Lanz, SY Jung, Y Bulynko, NT Le, DW Chan, C Ding, ... Cell 145 (5), 787-799, 2011 | 486 | 2011 |
| Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent D Gomes-Silva, M Mukherjee, M Srinivasan, G Krenciute, O Dakhova, ... Cell reports 21 (1), 17-26, 2017 | 276 | 2017 |
| Transgenic expression of IL15 improves antiglioma activity of IL13Rα2-CAR T cells but results in antigen loss variants G Krenciute, BL Prinzing, Z Yi, MF Wu, H Liu, G Dotti, IV Balyasnikova, ... Cancer immunology research 5 (7), 571-581, 2017 | 274 | 2017 |
| CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity CR Lazzarotto, NL Malinin, Y Li, R Zhang, Y Yang, GH Lee, E Cowley, ... Nature biotechnology 38 (11), 1317-1327, 2020 | 186 | 2020 |
| Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity B Prinzing, CC Zebley, CT Petersen, Y Fan, AA Anido, Z Yi, P Nguyen, ... Science translational medicine 13 (620), eabh0272, 2021 | 165 | 2021 |
| Inducible activation of MyD88 and CD40 in CAR T cells results in controllable and potent antitumor activity in preclinical solid tumor models M Mata, C Gerken, P Nguyen, G Krenciute, DM Spencer, S Gottschalk Cancer discovery 7 (11), 1306-1319, 2017 | 164 | 2017 |
| Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours CL Flugel, RG Majzner, G Krenciute, G Dotti, SR Riddell, DL Wagner, ... Nature Reviews Clinical Oncology 20 (1), 49-62, 2023 | 141 | 2023 |
| Optimizing EphA2-CAR T cells for the adoptive immunotherapy of glioma Z Yi, BL Prinzing, F Cao, S Gottschalk, G Krenciute Molecular Therapy Methods & Clinical Development 9, 70-80, 2018 | 114 | 2018 |
| Characterization and functional analysis of scFv-based chimeric antigen receptors to redirect T cells to IL13Rα2-positive glioma G Krenciute, S Krebs, D Torres, MF Wu, H Liu, G Dotti, XN Li, MS Lesniak, ... Molecular Therapy 24 (2), 354-363, 2016 | 108 | 2016 |
| Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignancies M Mamonkin, M Mukherjee, M Srinivasan, S Sharma, D Gomes-Silva, ... Cancer immunology research 6 (1), 47-58, 2018 | 93 | 2018 |
| cBAF complex components and MYC cooperate early in CD8+ T cell fate A Guo, H Huang, Z Zhu, MJ Chen, H Shi, S Yuan, P Sharma, JP Connelly, ... Nature 607 (7917), 135-141, 2022 | 91 | 2022 |
| RASA2 ablation in T cells boosts antigen sensitivity and long-term function J Carnevale, E Shifrut, N Kale, WA Nyberg, F Blaeschke, YY Chen, Z Li, ... Nature 609 (7925), 174-182, 2022 | 84 | 2022 |
| Next generation CAR T cells for the immunotherapy of high-grade glioma CT Petersen, G Krenciute Frontiers in oncology 9, 69, 2019 | 81 | 2019 |
| Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery D Haydar, H Houke, J Chiang, Z Yi, Z Odé, K Caldwell, X Zhu, KS Mercer, ... Neuro-oncology 23 (6), 999-1011, 2021 | 77 | 2021 |
| Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight CA Land, PR Musich, D Haydar, G Krenciute, Q Xie Journal of translational medicine 18, 1-13, 2020 | 72 | 2020 |
| Adoptive transfer of IL13Rα2-specific chimeric antigen receptor T cells creates a pro-inflammatory environment in glioblastoma KC Pituch, J Miska, G Krenciute, WK Panek, G Li, T Rodriguez-Cruz, ... Molecular therapy 26 (4), 986-995, 2018 | 69 | 2018 |
| Nuclear BAG6-UBL4A-GET4 complex mediates DNA damage signaling and cell death G Krenciute, S Liu, N Yucer, Y Shi, P Ortiz, Q Liu, BJ Kim, AO Odejimi, ... Journal of Biological Chemistry 288 (28), 20547-20557, 2013 | 48 | 2013 |
| Route of 41BB/41BBL costimulation determines effector function of B7-H3-CAR. CD28ζ T cells P Nguyen, E Okeke, M Clay, D Haydar, J Justice, C O’Reilly, ... Molecular Therapy-Oncolytics 18, 202-214, 2020 | 47 | 2020 |
| MyD88/CD40 signaling retains CAR T cells in a less differentiated state B Prinzing, P Schreiner, M Bell, Y Fan, G Krenciute, S Gottschalk JCI insight 5 (21), 2020 | 41 | 2020 |
| Engineering naturally occurring CD7− T cells for the immunotherapy of hematological malignancies A Freiwan, JT Zoine, JC Crawford, A Vaidya, SA Schattgen, JA Myers, ... Blood, The Journal of the American Society of Hematology 140 (25), 2684-2696, 2022 | 36 | 2022 |
